The United States pays prices for brand-name drugs that are estimated to be 256% higher than other wealthy nations.1 As the accelerated approval of aducanumab for Alzheimer disease shows, high prices (announced price for aducanumab is $56 000 per year) extend to drugs that are promising but have not been shown by randomized clinical trials to provide long-term clinical benefits. Today, many new high-cost cancer medications (such as belantamab mafodotin-blmf and lapatinib) have become available for use through the accelerated approval pathway.
Frank RG, Emanuel EJ. Paying for Cancer Drugs That Prove Their Benefit. JAMA. 2021;326(16):1579–1580. doi:10.1001/jama.2021.18308
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.